<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532620</url>
  </required_header>
  <id_info>
    <org_study_id>BZ-1702</org_study_id>
    <nct_id>NCT03532620</nct_id>
  </id_info>
  <brief_title>China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension</brief_title>
  <acronym>CAMPUS</acronym>
  <official_title>A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Tao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to test the hypothesis that Pitavastatin treatment
      compared to Atorvastatin, in patients with dyslipidemia, prediabetes and hypertension, will
      have less adverse effect on Hemoglobin A1C (HbA1C), which represents long-term glucose
      metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the 12 months of the study procedure, the 3rd month is what we called the &quot;check
      point&quot;. At this point, participants' plasma LDL-C will be measured whether it reached
      individual standard or not. If the results didn't meet the particular LDL-C standard, the
      participants would be adjusted the drug dosage (pitavastatin 4mg/day, atorvastatin 40mg/day).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in hemoglobin A1c levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of HbA1C values at study initiation and study completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in FPG levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of fasting plasma glucose (FPG) values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in OGTT-2h PG levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of oral glucose tolerance test (OGTT)-2h plasma glucose (PG) values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in LDL-C normalization state</measure>
    <time_frame>Month 3 and 12</time_frame>
    <description>Proportion of subjects in each group who achieved low-density lipoprotein cholesterol (LDL-C) target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in high-density lipoprotein cholesterol (HDL-C) levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of HDL-C values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total cholesterol (TC) levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of TC values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in triglycerides (TG) levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of TG values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in inflammatory parameters</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of C-reactive protein (CRP) values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular disease (CVD) events</measure>
    <time_frame>Month 12</time_frame>
    <description>Incidence of cardiovascular disease (CVD) events, including acute coronary syndrome, stable coronary artery disease, ischemic cardiomyopathy etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure levels</measure>
    <time_frame>Month 12</time_frame>
    <description>Change from baseline in systolic and diastolic blood pressure levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vascular endothelial function</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of brachial-ankle pulse wave velocity (baPWV) values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in left ventricular mass index</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of left ventricular mass index (LVMI) values at study initiation and study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in carotid intima-media thickness</measure>
    <time_frame>Month 12</time_frame>
    <description>Change of carotid intima-media thickness (CIMT) values at study initiation and study completion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Month 12</time_frame>
    <description>Incidence of adverse events (AEs) after treatment initiation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Prediabetic State</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>pitavastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin Calcium + lifestyle modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin Calcium + lifestyle modification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin Calcium</intervention_name>
    <description>In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the &quot;check point&quot;. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.</description>
    <arm_group_label>pitavastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium</intervention_name>
    <description>In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the &quot;check point&quot;. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.</description>
    <arm_group_label>atorvastatin</arm_group_label>
    <other_name>Lipitor®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years old;

          2. IFG: 5.6mmol/L (100mg/dl)≤FPG＜7.0mmol/L (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)≤OGTT
             2-h PG＜11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4% (39-47mmol/mol);

          3. 2.6mmol/L (100mg/dl)≤LDL-C≤5.2mmol/L (200mg/dl), and TG＜5.7mmol/L (500mg/dl);

          4. 130mmHg≤SBP＜180mmHg, or 80mmHg≤DBP＜110mmHg or ongoing anti-hypertensive therapy;

          5. Patients volunteered for the study and signed informed consent.

        Exclusion Criteria:

          1. Past history of hypersensitivity to the study drug;

          2. Diagnosed diabetes;

          3. Severe liver disease (including ALT or AST≥2.5-fold the normal upper limit), biliary
             obstruction;

          4. Ongoing treatment with cyclosporine within 2 weeks;

          5. Renal dysfunction, including endogenous creatinine clearance male＜120ml/min,
             female＜105ml/min, serum creatinine≥2mg/dl (186umol/L), Renal function progressive
             decline, GFR＜30ml•min-1•1.73m-2;

          6. Diagnosed or past history of ASCVD (including ACS, SCAD, revascularization, ICM,
             ischemic stroke, TIA, PASD, etc.

          7. SBP≥180mmHg, or DBP≥110mmHg;

          8. Ongoing treatment with Beta blockers, Diuretic;

          9. Secondary hypertension, including SAS, PA, RAS, pheochromocytoma, Cushing's syndrome,
             aorta diseases, drug induced hypertension;

         10. Ongoing treatment with statins, fibrates, and/or cation exchange resins within 2
             weeks;

         11. Pancreatic disease;

         12. History of gastrectomy, short bowel syndrome;

         13. Ongoing hormone replacement therapy;

         14. Diagnosed or suspected malignant tumor;

         15. Familial hypercholesterolemia;

         16. Any diseases may limit the efficacy or safety of the study;

         17. Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to
             become pregnant during study participation;

         18. Patient who was not judged as eligible by the investigator/coinvestigator.

               -  IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose
                  tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin
                  A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic
                  blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST
                  aspartate aminotransferase, GFR glomerular filtration rate, ASCVD
                  arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable
                  coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic
                  attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA
                  primary aldosteronism, RAS renal arterial stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Tao, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Tao, MD,PhD</last_name>
    <phone>+8613922191609</phone>
    <email>taojungz123@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianning Zhang</last_name>
    <phone>+8615521264372</phone>
    <email>ningjenny@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fourth People's Hospital of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Yue, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruihua Yue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Tao, MD,PhD</last_name>
      <phone>+8613922191609</phone>
      <email>taojungz123@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianning Zhang</last_name>
      <phone>+8615521264372</phone>
      <email>ningjenny@yeah.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Tao, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenchao Qu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wenchao Qu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jun Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Jiang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xin Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhongshan City</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Feng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Li Feng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heping Gu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Heping Gu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yichang Central Hospital</name>
      <address>
        <city>Yichang</city>
        <state>Hubei</state>
        <zip>443003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiawang Ding, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jiawang Ding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of TCM</name>
      <address>
        <city>Taizhou</city>
        <state>Jiangsu</state>
        <zip>214504</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongguang Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yongguang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruxing Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruxing Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital of Jiangsu province</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shenghu He, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shenghu He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Qinghai</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Bai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Feng Bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yantaishan Hospital, Yantai</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lan Zhao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lan Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N, The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S17-29. doi: 10.1016/j.jacl.2014.02.012.</citation>
    <PMID>24793439</PMID>
  </reference>
  <reference>
    <citation>Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2032-43. doi: 10.1056/NEJMoa1600177. Epub 2016 Apr 2.</citation>
    <PMID>27039945</PMID>
  </reference>
  <reference>
    <citation>Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vöhringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;132(19):1825-33. doi: 10.1161/CIRCULATIONAHA.115.016759. Epub 2015 Oct 2.</citation>
    <PMID>26432671</PMID>
  </reference>
  <reference>
    <citation>Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, Iwama M, Watanabe T, Nishigaki K, Takemura G, Noda T, Watanabe S, Minatoguchi S. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years' follow-up. Circ J. 2012;76(12):2755-62. Epub 2012 Aug 8.</citation>
    <PMID>22878405</PMID>
  </reference>
  <reference>
    <citation>Yoshika M, Komiyama Y, Masuda M, Yokoi T, Masaki H, Ohkura H, Takahashi H. Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists. Clin Exp Hypertens. 2010;32(6):341-6. doi: 10.3109/10641961003628460.</citation>
    <PMID>21028996</PMID>
  </reference>
  <reference>
    <citation>Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.</citation>
    <PMID>12551878</PMID>
  </reference>
  <reference>
    <citation>Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, Uchiyama S, Nakamura H; Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009 Feb;53(2):135-41. doi: 10.1161/HYPERTENSIONAHA.108.120584. Epub 2008 Dec 22.</citation>
    <PMID>19104004</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.</citation>
    <PMID>18997196</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J, Glynn RJ. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for &quot;intermediate risk&quot;. Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):447-52. doi: 10.1161/CIRCOUTCOMES.110.938118. Epub 2010 Aug 24.</citation>
    <PMID>20736443</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jun Tao</investigator_full_name>
    <investigator_title>Director, Head of the Department of Hypertension and Cardiovascular Disease, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>Prediabetic State</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, Statistical Analysis Plan, Clinical Study Report are planned to be available to other researchers. The information will be published on scientific journal and is anticipated to be available in public no more than a year after the study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

